ACTU vs ADAG

Actuate Therapeutics, Inc. vs Adagene Inc. — Valuation Comparison 2026

ACTU

Biotechnology
Actuate Therapeutics, Inc.
Quality
3.7
out of 10
Value Trap
12
SAFE
Price
$2.08
Last close
Models
7/13
Active
VS

ADAG

Biotechnology
Adagene Inc.
Quality
7.2
out of 10
Value Trap
36
LOW
Price
$3.94
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType ACTU Fair ValueACTU Upside ADAG Fair ValueADAG Upside
Bayesian DCF Intrinsic $0.74 -64.6% $1.38 -65.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.04 -98.6% $0.34 -91.2%
Dynamic NAV Asset-Based $0.85 -59.2% $0.67 -83.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ACTU vs ADAG — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ACTU vs ADAG — Which Stock Is More Undervalued?

ADAG scores higher with a 7.2/10 quality rating vs ACTU's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Actuate Therapeutics, Inc. (ACTU) and Adagene Inc. (ADAG) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ACTU currently trades at $2.08 with a QOC of 3.7/10, while ADAG trades at $3.94 with a QOC of 7.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).